LLNL licensee and collaborators develop novel medicines to combat autoimmune diseases

People afflicted with autoimmune diseases may someday receive help through treatments now under development by a Lawrence Livermore National Laboratory licensee and its' collaborations with two major pharmaceutical companies.

Related Keywords

Foster City ,Michigan ,United States ,Ann Arbor ,Paul Hoeprich ,Nicholas Fischer ,Yash Vaishnav ,Craig Blanchette ,David Giljohann ,Elsie Quaite Randall ,Emily Henderson ,Amgen ,Lawrence Livermore National Laboratory ,Gilead Sciences ,Department Of Energy ,Genentech ,Lab Diagnostics ,Laboratory Directed Research ,Gilead Sciences Inc ,Partnerships Office ,Us Food Drug Administration ,Amgen Inc ,Lab Innovation ,Defense Threat Reduction Agency ,California Based Gilead Sciences ,Thousand Oaks California Based ,Automation Industry Focus ,Drug Administration ,Defense Threat Reduction ,Arthritis ,Drugs ,Laboratory ,Lupus ,Reclinical ,Research ,Rheumatoid Arthritis ,Technology ,Herapeutics ,Vaccine ,